461 related articles for article (PubMed ID: 18000942)
21. Appropriate biochemical parameters in first-trimester screening for Down syndrome.
Cuckle HS; van Lith JM
Prenat Diagn; 1999 Jun; 19(6):505-12. PubMed ID: 10416963
[TBL] [Abstract][Full Text] [Related]
22. First-trimester Down syndrome screening using additional serum markers with and without nuchal translucency and cell-free DNA.
Johnson J; Pastuck M; Metcalfe A; Connors G; Krause R; Wilson D; Cuckle H
Prenat Diagn; 2013 Nov; 33(11):1044-9. PubMed ID: 23836291
[TBL] [Abstract][Full Text] [Related]
23. Combining inhibin A with existing second-trimester markers in maternal serum screening for Down's syndrome.
Cuckle HS; Holding S; Jones R; Groome NP; Wallace EM
Prenat Diagn; 1996 Dec; 16(12):1095-100. PubMed ID: 8994244
[TBL] [Abstract][Full Text] [Related]
24. Second trimester prenatal screening for Down's syndrome in Mainland Chinese subjects using double-marker analysis of α-fetoprotein and β-human chorionic gonadotropin combined with measurement of nuchal fold thickness.
Liu F; Liang H; Jiang X; Zhang Y; Xue L; Yang C; Cheng J; Liu P; Liu Y; Guo X
Ann Acad Med Singap; 2011 Jul; 40(7):315-8. PubMed ID: 21870022
[TBL] [Abstract][Full Text] [Related]
25. Screening for trisomy 21 by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: a German multicenter study.
von Kaisenberg CS; Gasiorek-Wiens A; Bielicki M; Bahlmann F; Meyberg H; Kossakiewicz A; Pruggmayer M; Kamin G; Fritzer E; Harris C; Arnold N;
J Matern Fetal Neonatal Med; 2002 Aug; 12(2):89-94. PubMed ID: 12420837
[TBL] [Abstract][Full Text] [Related]
26. First-trimester or second-trimester screening, or both, for Down's syndrome.
Malone FD; Canick JA; Ball RH; Nyberg DA; Comstock CH; Bukowski R; Berkowitz RL; Gross SJ; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; Dukes K; Bianchi DW; Rudnicka AR; Hackshaw AK; Lambert-Messerlian G; Wald NJ; D'Alton ME;
N Engl J Med; 2005 Nov; 353(19):2001-11. PubMed ID: 16282175
[TBL] [Abstract][Full Text] [Related]
27. Maternal serum free-beta-chorionic gonadotrophin, pregnancy-associated plasma protein-A and fetal nuchal translucency thickness at 10-13(+6) weeks in relation to co-variables in pregnant Saudi women.
Ardawi MS; Nasrat HA; Rouzi AA; Qari MH; Al-Qahtani MH; Abuzenadah AM
Prenat Diagn; 2007 Apr; 27(4):303-11. PubMed ID: 17269128
[TBL] [Abstract][Full Text] [Related]
28. Second-trimester Down syndrome maternal serum screening in twin pregnancies: impact of chorionicity.
Muller F; Dreux S; Dupoizat H; Uzan S; Dubin MF; Oury JF; Dingeon B; Dommergues M
Prenat Diagn; 2003 Apr; 23(4):331-5. PubMed ID: 12673641
[TBL] [Abstract][Full Text] [Related]
29. Combined measurement of fetal nuchal translucency, maternal serum free beta-hCG, and pregnancy-associated plasma protein A for first-trimester Down's syndrome screening.
Tsai MS; Huang YY; Hwa KY; Cheng CC; Lee FK
J Formos Med Assoc; 2001 May; 100(5):319-25. PubMed ID: 11432311
[TBL] [Abstract][Full Text] [Related]
30. First-trimester screening for trisomy 21 with adjustment for biochemical results of previous pregnancies.
Wright D; Syngelaki A; Birdir C; Bedei I; Nicolaides KH
Fetal Diagn Ther; 2011; 30(3):194-202. PubMed ID: 21709403
[TBL] [Abstract][Full Text] [Related]
31. Uptake of prenatal screening for chromosomal anomalies: impact of test results in a previous pregnancy.
Spencer K
Prenat Diagn; 2002 Dec; 22(13):1229-32. PubMed ID: 12478639
[TBL] [Abstract][Full Text] [Related]
32. Two-stage first-trimester screening for trisomy 21 by ultrasound assessment and biochemical testing.
Kagan KO; Staboulidou I; Cruz J; Wright D; Nicolaides KH
Ultrasound Obstet Gynecol; 2010 Nov; 36(5):542-7. PubMed ID: 20503223
[TBL] [Abstract][Full Text] [Related]
33. Maternal thyroid function at 11-13 weeks of gestation in fetal trisomies 21 and 18.
Ashoor G; Maiz N; Cuckle H; Jawdat F; Nicolaides KH
Prenat Diagn; 2011 Jan; 31(1):33-7. PubMed ID: 21210478
[TBL] [Abstract][Full Text] [Related]
34. Screening of maternal serum for fetal Down's syndrome in the first trimester.
Haddow JE; Palomaki GE; Knight GJ; Williams J; Miller WA; Johnson A
N Engl J Med; 1998 Apr; 338(14):955-61. PubMed ID: 9521983
[TBL] [Abstract][Full Text] [Related]
35. Comparison of second-trimester maternal serum free-beta-human chorionic gonadotropin and alpha-fetoprotein between normal singleton and twin pregnancies: a population-based study.
Zheng MM; Hu YL; Zhang CY; Ru T; Liu QL; Xu BY; Chen QG; Xu ZF; Zhang Y; Zhong XL
Chin Med J (Engl); 2010 Mar; 123(5):555-8. PubMed ID: 20367980
[TBL] [Abstract][Full Text] [Related]
36. Dimeric inhibin A as a marker for Down's syndrome in early pregnancy.
Aitken DA; Wallace EM; Crossley JA; Swanston IA; van Pareren Y; van Maarle M; Groome NP; Macri JN; Connor JM
N Engl J Med; 1996 May; 334(19):1231-6. PubMed ID: 8606718
[TBL] [Abstract][Full Text] [Related]
37. Screening for aneuploidies by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-13+6 gestational weeks.
Karadzov-Orlić N; Egić A; Filimonović D; Marinković M; Damnjanović-Pazin B; Milovanović Z; Joksić I; Branković S; Lukić R; Mandić V; Cerović N; Mojović D; Plamenac S; Stanković M; Maglić D; Mikovć Z
Srp Arh Celok Lek; 2012; 140(9-10):606-11. PubMed ID: 23289277
[TBL] [Abstract][Full Text] [Related]
38. Practical strategies in contingent sequential screening for Down syndrome.
Benn P; Wright D; Cuckle H
Prenat Diagn; 2005 Aug; 25(8):645-52. PubMed ID: 16049988
[TBL] [Abstract][Full Text] [Related]
39. Screening for trisomy 18 by maternal age, fetal nuchal translucency, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Kagan KO; Wright D; Maiz N; Pandeva I; Nicolaides KH
Ultrasound Obstet Gynecol; 2008 Sep; 32(4):488-92. PubMed ID: 18726925
[TBL] [Abstract][Full Text] [Related]
40. Second trimester two-step trisomy 18 screening using maternal serum markers.
Muller F; Sault C; Lemay C; Roussel-Mizon N; Forestier F; Frendo JL;
Prenat Diagn; 2002 Jul; 22(7):605-8. PubMed ID: 12124697
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
